EP2158214B1 - Analogues du glucagon - Google Patents
Analogues du glucagon Download PDFInfo
- Publication number
- EP2158214B1 EP2158214B1 EP08762369A EP08762369A EP2158214B1 EP 2158214 B1 EP2158214 B1 EP 2158214B1 EP 08762369 A EP08762369 A EP 08762369A EP 08762369 A EP08762369 A EP 08762369A EP 2158214 B1 EP2158214 B1 EP 2158214B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- glucagon
- peptide
- glp
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention relates to glucagon analogues and their medical use, for example in the treatment of excess food intake, obesity and excess weight.
- Oxyntomodulin is known to activate both the GLP-1 (glucagon-like peptide 1) receptor and the glucagon receptor, and it has been suggested that the GLP-1 receptor is essential for the anorectic function of Oxm.
- Oxyntomodulin is derived from proglucagon, which is a 158 amino acid peptide processed differently in different organs. Whereas glucagon (29 amino acids in length; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr) is produced in the pancreas, the longer 37 amino acid peptide oxyntomodulin (His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-Ly
- Oxyntomodulin consists of the full length glucagon and a C-terminal octapeptide (termed “intervening peptide 1" or IP-1, sequence Lys-Arg-Asn-Arg-Asn-Asn-Ile-Ala). Both glucagon and IP-1 fail to affect food intake when administered separately ( Dakin, C.L. et al. (2001), Endocrin. 142, 4244-4250 ).
- Both peptides are a substrate for the endogenous enzyme dipeptidyl peptidase which cleaves at the C-terminal side of Ser2 ( Zhu, L. et al. (2003), J. Biol. Chem. 278, 22418-22423 ). Moreover it is found that a proteolytic fragment of glucagon is liberated following cleavage of glucagon at the Arg17-Arg18 amino acid doublet ( Blache, P. at al. (1993) J. Biol. Chem. 268, 21748-21753 ).
- the present inventors believe that the anorectic effects of Oxm can be mimicked by analogues of glucagon which have an increased selectivity for the GLP-1 receptor. This enables a peptide to be used which has pharmacological effects similar to oxyntomodulin, but potentially has a shorter primary peptide chain like that of glucagon to facilitate production through solid phase peptide synthesis.
- glucagon agonist activity may also be required for the anorectic effect to be demonstrated.
- the invention provides a glucagon analogue peptide of the formula: R 1 -Z 1 -HSQGTFTSDYSKYLDRARADDFVAWLKST-Z 2 -R 2 wherein:
- the invention further relates to a method of promoting weight loss or preventing weight gain in a subject, by administering said glucagon analogue peptide to the subject.
- the peptide may be useful for the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis.
- glucagon analogue peptide in the preparation of a medicament for promoting weight loss or preventing weight gain in a subject.
- the methods and uses of the invention also extend to nucleic acids encoding the glucagon analogue peptide, expression vectors comprising such nucleic acids, and host cells containing such nucleic acids or expression vectors.
- glucagon analogue peptide for use in a method of promoting weight loss or preventing weight gain in a subject.
- glucagon analogue peptide amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid sequence, amino acid, expression vector or host cell as described, for use in a method of medical treatment.
- the glucagon analogue peptide may have higher GLP-1 receptor selectivity than human glucagon. Typically it also has glucagon agonist activity, i.e. it is a GLP-1/glucagon co-agonist.
- the GLP-1 or glucagon agonist activity of any given glucagon analogue peptide may be quantified by determining an EC50 value for that peptide in a selected assay for GLP-1 or glucagon activity.
- the EC50 value is a measure of the concentration at which half of that compound's maximal activity in the particular assay is achieved.
- the EC50 value in an assay for GLP-1 or glucagon agonist activity will be referred to as EC50[GLP-1] and EC50[Glu] respectively.
- EC50[GLP-1] and EC50[Glu] respectively.
- the ratio EC50[Glu]/EC50[GLP-1] for the glucagon analogue peptides may be greater than the ratio EC50[Glu]/EC50[GLP-1] for glucagon. This may be interpreted to mean that the glucagon analogue peptide has a greater selectivity for GLP-1 receptor than glucagon.
- the glucagon analogue peptide may have the formula: H-HSQGTFTSDYSKYLDRARADDFVAWLKST-NH 2 or may be a pharmaceutically acceptable salt, metal ion coordination complex, ester or hydrate thereof;
- the invention further provides a nucleic acid encoding the glucagon analogue peptide of the invention, an expression vector comprising such a nucleic acid, and a host cell containing such a nucleic acid or expression vector.
- the present invention also relates to providing compounds that have anti-obesity and/or feeding reducing activity in a mammal or human being in need of treatment
- the substitution at position 27 may improve oxidative stability relative to human glucagon.
- the substitutions at positions 20, 24 and 28 may increase stability against deamidation relative to human glucagon.
- the glucagon analogue of the invention may therefore exhibit enhanced stability towards deamidation, and/or towards oxidative degradation, relative to the wild type glucagon.
- the peptide of this invention may exhibit enhanced stability towards in vivo degradation, perhaps due to the substitutions in the twin arginine site at position 17-18 of human glucagon.
- the present invention provides a composition comprising a glucagon analogue peptide as defined herein, or a salt, thereof metal ion coordination complex, ester or hydrate in admixture with a carrier.
- the composition is a pharmaceutically acceptable composition and the carrier is a pharmaceutically acceptable carrier.
- the glucagon peptide analogue may be a pharmaceutically acceptable acid addition salt of the glucagon analogue.
- the glucagon analogue peptides described find use in preventing weight gain or promoting weight loss.
- preventing is meant inihibiting or reducing weight gain when compared to the absence of treatment, and is not necessarily meant to imply complete cessation of weight gain.
- the peptides can be used for direct or indirect therapy of any condition caused or characterised by excess body weight, such as the treatment and/or prevention of obesity, and/or prevention of morbid obesity and metabolic syndrome, which is characterized by hypertriglyceridaemia, low HDL-cholesterol, elevated apolipoprotein B, small dense LDL particles, inflammatory profile, insulin resistance, hyperinsulinaemia, glucose intolerence, impaired fibrinolysis as well as endothelial and mitochondrial dysfunction.
- Metabolic syndrome is highly associated with increased prevalence of type-2 diabetes, hypertension, arteriosclerosis and coronary heart diseases.
- the peptides may cause a decrease in food intake and/or increased energy expenditure, resulting in the observed effect on body weight.
- the invention extends to expression vectors comprising the above-described nucleic acid sequence, optionally in combination with sequences to direct its expression, and host cells transformed with the expression vectors.
- the host cells are capable of expressing and secreting the glucagon analogue.
- the present invention provides a method of producing the glucagon analogue, the method comprising culturing the host cells under conditions suitable for expressing the glucagon analogue and purifying the glucagon analogue thus produced.
- Salts include pharmaceutically acceptable salts such as acid addition salts and basic salts.
- acid addition salts include hydrochloride salts, citrate salts and acetate salts.
- basic salts include salts where the cation is selected from alkali metals, such as sodium and potassium, alkaline earth metals, such as calcium, and ammonium ions + N (R 3 ) 3 (R 4 ), where R 3 and R 4 independently designate optionally substituted C 1-6 -alkyl, optionally substituted C 2-6 -alkenyl, optionally substituted aryl, or optionally substituted heteroaryl.
- glucagon analogues of the invention are coordination complexes with metal ions such as Mn 2+ and Zn 2+ , esters such as in vivo hydrolysable esters, and hydrates, Esters can be formed between hydroxyl or carboxylic acid groups present in the compound and an appropriate carboxylic acid or alcohol reaction partner, using techniques well known in the art.
- the analogue may comprise an additional N- or C-terminal peptide sequence of 3-20 amino acids, for example to stabilise the conformation and/or secondary structure of the glucagon analogue peptide, and/or to make the glucagon analogue peptide more resistant to enzymatic hydrolysis, e.g. as described in WO99/46283 .
- additional N- and C-terminal peptide sequences are designated Z 1 and Z 2 respectively.
- Z 1 and Z 2 each independently represent a peptide sequence of 3-20 or 4-20 amino acid residues, e.g. in the range of 4-15, more preferably in the range of 4-10 in particular in the range of 4-7 amino acid residues, e.g., of 4, 5, 6 or 7 amino acid residues, such as 6 amino acid residues.
- Each of the amino acid residues in the peptide sequences Z may independently be selected from Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Orn.
- the amino acid residues are selected from Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Orn, and Met, as well as amino acids falling within formula I as defined in WO01/04156 , e.g., Dbu (2,4 diaminobutyric acid) or Dpr (2,3-diaminopropanoic acid), and more preferably may be selected exclusively from Glu, Lys, and Met, especially Lys.
- the above-mentioned amino acids may have either D- or L-configuration, but preferably the above-mentioned amino acids have an L-configuration.
- sequences Z are sequences of four, five, six or seven consecutive lysine residues (i.e. Lys 3 , Lys 4 , Lys 5 , Lys 6 or Lys 7 ), and particularly five or six consecutive lysine residues. Exemplary sequences Z are shown in WO 01/04156 .
- Z 1 is absent.
- Z 2 may be either present or absent.
- R 1 may be H
- Z 2 is present R 2 may be OH.
- this additional peptide sequence typically has no more than 25% sequence identity with the corresponding sequence of the IP-1 portion of OXM (which has the sequence Lys-Arg-Asn-Arg-Asn-Asn-Ile-Ala).
- Percent (%) amino acid sequence identity with respect to the another polypeptide sequence (e.g. glucagon, Oxm or IP-1) is calculated as the percentage of amino acid residues in a glucagon analogue peptide sequence that are identical with corresponding amino acid residues in the corresponding sequence of that other polypeptide when the two are aligned with one another, introducing gaps for optimal alignment if necessary.
- the glucagon analogue peptides described in this specification may have higher GLP-1 receptor selectivity than human glucagon. In some embodiments, they may also have higher GLP-1 agonist activity than human glucagon.
- Binding of the relevant compounds to GLP-1 or glucagon receptors may be used as an indication of agonist activity, but in general it is preferred to use a biological assay which measures intracellular signalling caused by binding of the compound to the relevant receptor.
- a biological assay which measures intracellular signalling caused by binding of the compound to the relevant receptor.
- production of cyclic AMP (cAMP) is often used to monitor both GLP-1 and glucagon receptor activity, and hence can be used to determine glucagon analogue peptide agonist activity towards each type of receptor.
- the GLP-1 receptor and/or the glucagon receptor may have the sequence of the receptors as described in the examples.
- the assays may make use the human glucagon receptor (Glucagon-R) having primary accession number P47871 (GI 1346144) and/or the human glucagon-like peptide 1 receptor (GLP-1 R) having primary accession number P43220 (GI 1169956).
- Glucagon-R human glucagon receptor
- GLP-1 R human glucagon-like peptide 1 receptor
- EC50 values may be used as a numerical measure of agonist activity.
- An EC50 value is a measure of the concentration of a compound requried to achieve half of that compound's maximal activity in a particular assay.
- a compound having EC50[GLP-1] lower than the EC50[GLP-1] of glucagon in a particular assay may be considered to have a higher GLP-1 agonist activity than glucagon.
- high selectivity for GLP-1 is meant that the ratio of the compound's GLP-1 agonist activity to its glucagon agonist activity is higher than that of glucagon. That is to say, for a particular level of glucagon agonist activity, the analogue will display a higher level of GLP-1 agonist activity than glucagon. Since the EC50 values are inversely related to activity, this means that the ratio EC50[Glu]/EC50[GLP-1] for the glucagon analogue peptide may be greater than the ratio EC50[Glu]/EC50[GLP-1] for glucagon.
- the glucagon analogue has a higher GLP-1 agonist activity than human glucagon. (Accordingly, it may have a lower EC50[GLP-1] than the EC50[GLP-1] for human glucagon.)
- the GLP-1 agonist activity may be substantially similar to, or lower than, human glucagon, provided that the ratio of GLP-1/glucagon agonist activity remains higher for the analogue than for human glucagon (i.e., the glucagon agonist activity is correspondingly reduced).
- the glucagon analogue peptide also has glucagon agonist activity, i.e. it is a GLP-1/glucagon co-agonist.
- the glucagon analogue peptide may have substantially similar glucagon agonist activity to human glucagon (indeed, it may have a higher activity provided that the GLP-1 agonist activity is correspondingly increased). However the glucagon agonist activity may also be lower than that of human glucagon, as long as it is sufficient for anorectic activity.
- glucagon analogues e.g. based on those described below.
- Degradation may occur as oxidation, hydrolysis and deamidation, depending on the identity and position of the amino acids in any given glucagon analogue, and conditions such as pH, solution and temperature.
- the compounds can be ranked according to chemical stability, when the compounds are incubated under stressed conditions (i.e. conditions likely to cause degradation) and subsequently analysed for content of remaining intact peptide.
- stressed conditions i.e. conditions likely to cause degradation
- the knowledge gained about major degradation products obtained under stressed conditions will be important for any later analytical method development.
- the skilled person will also be capable of designing methods (e.g. quantitative methods) for detection of glucagon analogues in complex environments or solutions (e.g. plasma, urine, tissue homogenates, cell homogenates, saliva or similar) to investigate the absorption, distribution, metabolism and excretion of the glucagon analogues after administration to mammals or as part of functional studies of in vitro cell systems.
- methods e.g. quantitative methods
- solutions e.g. plasma, urine, tissue homogenates, cell homogenates, saliva or similar
- a quantitative assay can be based on antibodies raised against the glucagon analogues or fragments thereof.
- the antibodies obtained from the immunized animals can be used for quantitative assays.
- a direct sandwich ELISA can be prepared using a first antibody with affinity of one part of the molecule immobilized in a multi-well plate. The sample is then applied to the wells and the glucagon analogue is captured by the first antibody. The captured glucagon analogue is then recognized by a second antibody with affinity for another part of the glucagon analogue.
- the second antibody can be labeled with an enzyme (horseradish peroxidase, alkaline phosphatase or beta-galactosidase) or a radioisotope.
- the amount of captured glucagon analogue can then be detected by addition of a colorimetric substrate or direct counting of radioemission or by scintillation.
- the amount of captured glucagon analogue can be detected indirectly by addition of a labeled antibody with affinity for the second antibody.
- the concentration in the sample can be estimated from the response obtained from an external standard curve containing known amounts of glucagon analogue.
- the antibodies can be used to prepare a direct competitive immuno assay, where an antibody specific for the glucagon analogue is immobilized on a multi-well plate and the sample incubated in the wells with a predefined fixed concentration of labeled glucagon analogue.
- the label can be an enzyme, a fluorophore, a radioisotope or biotin and detected using, for example, substrates (e.g. colorimetric, fluorometric or chemiluminiscent) specific for the enzymes, scintillation or avidin linked to an enzyme followed by detection as described above.
- substrates e.g. colorimetric, fluorometric or chemiluminiscent
- the amount of bound labeled glucagon analogue can be detected by an appropriate method and the concentration of glucagon analogue present in the sample derived from the response obtained from an external standard curve as described above.
- a quantitative assay can be based on liquid chromatography tandem mass spectroscopy methodology.
- the response from a fragment specific for the glucagon analogue to be studied is monitored upon fragmentation of the parent compound induced by collision with an inert gas (He or Ar).
- the sample components Prior to fragmentation the sample components can be separated by reversed phase chromatography or the sample can be injected directly in the mass spectrometer. If suitable the sample can be subjected to pretreatment (i.e., addition of protease inhibitors, protein precipitation, solid phase extraction, immuno-affinity extraction, etc).
- the concentration of glucagon analogue present in the sample is derived from the response obtained from an external standard curve as described above, potentially after correction of the response using an internal standard similar to the glucagon analogue to be studied.
- Specific antibodies against the glucagon analogues or fragments thereof can be induced in mammals and purified from the serum.
- the glucagon analogues or fragments can either be used directly with an adjuvant to immunize rabbits, mice or other mammals, or the glucagon analogues or fragments thereof can be chemically linked to a carrier molecule (i.e., keyhole limpet hemocyanin, ovalbumin, albumin etc.) and injected with an adjuvant.
- the injections can be repeated with 2-4 weeks intervals for extended periods to improve the affinity and selectivity of the antibodies.
- Polyclonal antibodies can be harvested directly from the serum. To obtain monoclonal antibodies.
- substrates e.g. colorimetric, fluorometric or chemiluminiscent
- glucagon analogues may be synthesized in a number of ways including for example, a method which comprises:
- peptide is sufficiently large (or produced as a fusion construct) and when the peptide only includes naturally occurring amino acids that can be translated from RNA in living organisms.
- nucleic acid fragments encoding the peptides of the invention are important chemical products.
- a further aspect of the present invention provides a nucleic acid molecule comprising a nucleic acid sequence encoding a glucagon analogue of the invention, where the peptide is comprised by naturally occurring amino acids.
- the nucleic acid fragments of the invention are either DNA or RNA fragments.
- nucleic acid fragments of the invention will normally be inserted in suitable vectors to form cloning or expression vectors carrying the nucleic acid fragments of the invention; such novel vectors are also part of the invention. Details of the construction of these vectors of the invention will be familiar to the skilled person and construction of such vectors will be well within the skilled person's ability.
- the expression product is either exported (secreted) out into the culture medium or carried on the surface of the transformed cell.
- peptides may be prepared in vitro in cell free systems. This is especially expedient in cases where the peptides could be toxic for putative host cells.
- the present invention also contemplates use of cell-free in vitro translation/expression in order to prepare the peptides of the invention.
- peptide fragments are prepared using at least 2 separate steps or methods, followed by ligation of the fragments to obtain the final peptide product.
- the compounds of the present invention may be formulated as pharmaceutical compositions prepared for storage or administration, and which comprise a therapeutically effective amount of a glucagon peptide of the present invention, or a pharmaceutically acceptable salt, metal ion coordination complex, ester or hydrate thereof, in a pharmaceutically acceptable carrier.
- the therapeutically effective amount of a compound of the present invention will depend on the route of administration, the type of mammal being treated, and the physical characteristics of the specific mammal under consideration. These factors and their relationship to determining this amount are well known to skilled practitioners in the medical arts. This amount and the method of administration can be tailored to achieve optimal efficacy, but will depend on such factors as weight, diet, concurrent medication and other factors, well known to those skilled in the medical arts.
- glucagon analogue, or a salt thereof is present in an amount effective in adjunctive therapy to improve glycemic control and induce prolonged weight loss in people with obesity and type II diabetes (e.g. treated with antidiabetics such as metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, insulin or a combination of antidiabetics) who have not achieved adequate glycemic control.
- antidiabetics such as metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, insulin or a combination of antidiabetics
- glucagon analogue or a salt thereof is administered in combination with one or more other anti-obesity agents
- one or more other anti-obesity agents such as Neuropeptide Y (NPY), Agouti-related protein (AGRP), Melanin concentrating hormone (MCH), Hypocretins/Orexins, Ghrelin, Galanin, Growth Hormone-releasing Hormone (GHRH), Dynorphin, Beta-Endorphin, Beacon, 26RFa, Adiponectin, POMC, CART, Neurotensin (NT), Cholecystokinin (CCK), Corticotropin-releasing Hormone (CRH), Urocortin, Tyrotropin-releasing Hormone (TRH), Glucagon-like Peptide-1 (GLP-1), Galanin-like Peptide (GALP), PYY(3-36), Leptin, Neuropeptide K (NPK), Calcitonin-gene Related Peptide (CGRP), Pro
- salts of the compound of the invention having an acidic moiety can be formed using organic and inorganic bases.
- Suitable salts formed with bases include metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, or magnesium salts; ammonia salts and organic amine salts, such as those formed with morpholine, thiomorpholine, piperidine; pyrrolidine, a mono-, di- or tri-lower alkylamine (e.g., ethyl-tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropylamine), or a mono-, di- or trihydroxy lower alkylamine (e.g., mono-, di- or triethanolamine).
- metal salts such as alkali metal or alkaline earth metal salts, for example sodium, potassium, or magnesium salts
- ammonia salts and organic amine salts such as those formed with
- salts can be formed using organic and inorganic acids.
- salts can be formed from the following acids: acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic, and camphorsulfonic as well as other known pharmaceutically acceptable acids.
- Amino acid addition salts can also be formed with amino acids such as lysine, glycine, or phenylalanine.
- a "therapeutically effective amount" of the peptide or pharmaceutical compositions of the present invention will vary depending upon the age, weight and mammalian species treated, the particular mode of administration and the desired effects and the therapeutic indication. Because these factors and their relationship to determining this amount are well known in the medical arts, the determination of therapeutically effective dosage levels, the amount necessary to achieve the desired result of preventing and/or treating excess body weight or obesity, including morbid obesity, metabolic syndrome, type-2 diabetes, hypertension, atherosclerois, arteriosclerosis and coronary heart diseases, as well as other medical indications disclosed herein, will be within the ambit of the skilled person.
- a therapeutically effective amount is one which reduces symptoms of a given condition or pathology, and preferably which normalizes physiological responses in an individual with the condition or pathology. Reduction of symptoms or normalization of physiological responses can be determined using methods routine in the art and may vary with a given condition or pathology.
- a therapeutically effective amount of a glucagon analogue or pharmaceutical composition is an amount which restores a measurable physiological parameter to substantially the same value (preferably to within + 30%, more preferably to within + 20%, and still more preferably, to within 10% of the value) of the parameter in an individual without the condition or pathology.
- administration of the compound or pharmaceutical composition of the present invention is commenced at lower dosage levels, with dosage levels being increased until the desired effect of preventing/treating the relevant medical indication, such as excess body weight or obesity, including morbid obesity, metabolic syndrome, type-2 diabetes, hypertension, atherosclerois, arteriosclerosis and coronary heart diseases, is achieved.
- the relevant medical indication such as excess body weight or obesity, including morbid obesity, metabolic syndrome, type-2 diabetes, hypertension, atherosclerois, arteriosclerosis and coronary heart diseases.
- doses may be between about 0.01 mg/kg and 100 mg/kg body weight, such as between about 0.01 mg/kg and 10 mg/kg body weight, for example between 10-100 ⁇ g/kg body weight.
- the chosen glucagon analogue is formulated with a carrier that is pharmaceutically acceptable and is appropriate for delivering the peptide by the chosen route of administration.
- peripheral parenteral routes include intravenous, intramuscular, subcutaneous, and intraperitoneal routes of administration.
- Certain compounds used in the present invention may also be amenable to administration by the oral, rectal, nasal, or lower respiratory routes. These are so-called non-parenteral routes.
- the present pharmaceutical composition comprises a glucagon analogue of the invention, or a pharmaceutically acceptable salt, metal ion coordination complex, ester or hydrate thereof and a pharmaceutically acceptable carrier.
- Suitable pharmaceutically acceptable carriers are those used conventionally with peptide-based drugs, such as diluents, excipients and the like.
- Pharmaceutically acceptable carriers for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985 ). For example, sterile saline and phosphate-buffered saline at slightly acidic or physiological pH may be used.
- pH buffering agents may be phosphate, citrate, acetate, tris/hydroxymethyl)aminomethane (TRIS), N-Tris(hydroxymethyl)methyl -3- aminopropanesulphonic acid (TAPS), ammonium bicarbonate, diethanolamine, histidine, which is a preferred buffer, arginine, lysine, or acetate or mixtures thereof.
- Preferred buffer ranges are pH 4-8, pH 6.5-8, more preferably pH 7-7.5.
- Preservatives such as para, meta, and ortho-cresol, methyl- and propylparaben, phenol, benzyl alcohol, sodium benzoate, benzoic acid, benzyl-benzoate, sorbic acid, propanoic acid, esters of p-hydroxybenzoic acid may be provided in the pharmaceutical composition.
- Stabilizers preventing oxidation, deamidation, isomerisation, racemisation, cyclisation, peptide hydrolysis, such as e.g. ascorbic acid, methionine, tryptophane, EDTA, asparagine, lysine, arginine, glutamine and glycine may be provided in the pharmaceutical composition.
- Stabilizers preventing aggregation, fibrillation and precipitation, such as Sodium dodecyl sulphate, polyethylene glycol, carboxymethyl cellulose, cyclodextrine may be provided in the pharmaceutical composition.
- Organic modifiers for solubilization or preventing aggregation, such as ethanol, acetic acid or acetate and salts thereof may be provided in the pharmaceutical composition.
- Isotonicity makers such as salts e.g. sodium chloride or most preferred carbohydrates e.g. dextrose, mannitol, lactose, trehalose, sucrose or mixtures thereof may be provided in the pharmaceutical composition.
- Detergents such as Tween 20, Tween 80, SDS, Poloxamers e.g. Pluronic F-68, Pluronic F-127, may be provided in the pharmaceutical composition.
- Dyes and even flavoring agents may be provided in the pharmaceutical composition.
- a pharmaceutically acceptable acid addition salt of the glucagon peptide analogue is provided for. Suspending agents may be used.
- Organic modifiers such as ethanol, tertiary-buthanol, 2-propanol, ethanol, glycerol, Polyethylene glycol may be provided in the pharmaceutical formulation for lyophilization of a lyophilized product.
- Bulking agents and isotonicity makers such as salt e.g. sodium chloride, carbohydrates e.g. dextrose, mannitol, lactose, trehalose, sucrose or mixtures thereof, aminoacids e.g. glycine, glutamate, or excipients such as cystein, lecithin or human serum albumin, or mixtures thereof may be provided in the pharmaceutical composition for lyophilization.
- compositions of the present invention may be formulated and used as tablets, capsules or elixirs for oral administration; suppositories for rectal administration; preferably sterile solutions or sterile powder or suspensions for injectable administration; and the like.
- the dose and method of administration can be tailored to achieve optimal efficacy but will depend on such factors as weight, diet, concurrent medication and other factors, which those skilled in the medical arts will recognize.
- injectable pharmaceutical compositions can be prepared in conventional forms, either as aqueous solutions or suspensions; lyophilized, solid forms suitable for reconstitution immediately before use or suspension in liquid prior to injection, or as emulsions. It is envisaged that the administration regimen for the peptide of the invention should be peripheral subcutaneous or nasal.
- Diluents for reconstitution of the lyophilized product may be a suitable buffer from the list above, water, saline, dextrose, mannitol, lactose, trehalose, sucrose, lecithin, albumin, sodium glutamate, cysteine hydrochloride; or water for injection with addition of detergents, such as Tween 20, Tween 80, poloxamers e.g.
- pluronic F-68 or pluronic F-127 polyethylene glycol, and or with addition of preservatives such as para-, meta-, and ortho-cresol, methyl- and propylparaben, phenol, benzyl alcohol, sodium benzoate, benzoic acid, benzyl-benzoate, sorbic acid, propanoic acid, esters of p-hydroxybenzoic acid, and or with addition of an organic modifier such as ethanol, acitic acid, citric acid, lactic acid or salts thereof.
- preservatives such as para-, meta-, and ortho-cresol, methyl- and propylparaben, phenol, benzyl alcohol, sodium benzoate, benzoic acid, benzyl-benzoate, sorbic acid, propanoic acid, esters of p-hydroxybenzoic acid, and or with addition of an organic modifier such as ethanol, acitic acid, citric acid, lactic acid or salts thereof.
- the injectable pharmaceutical compositions may contain minor amounts of non-toxic auxiliary substances, such as wetting agents, or pH buffering agents.
- Absorption enhancing preparations e.g., liposomes, detergents and organic acids may be utilized.
- the compounds are formulated for administration by infusion, e.g., when used as liquid nutritional supplements for patients on total parenteral nutrition therapy, or by injection, for example subcutaneously, intraperitoneal or intravenously, and are accordingly utilized as aqueous solutions in sterile and pyrogen-free form and optionally buffered to physiologically tolerable pH, e.g., a slightly acidic or physiological pH.
- Formulation for intramuscular administration may be based on solutions or suspensions in plant oil, e.g. canola oil, corn oil or soy bean oil. These oil based formulations may be stabilized by antioxidants e.g. BHA (butylated hydroxianisole) and BHT (butylated hydroxytoluene).
- the present peptide compounds may be administered in a vehicle, such as distilled water or in saline, phosphate buffered saline, 5% dextrose solutions or oils.
- a vehicle such as distilled water or in saline, phosphate buffered saline, 5% dextrose solutions or oils.
- the solubility of the glucagon analogue may be enhanced, if desired, by incorporating a solubility enhancer, such as detergents and emulsifiers.
- aqueous carrier or vehicle can be supplemented for use as injectables with an amount of gelatin that serves to depot the glucagon analogue at or near the site of injection, for its slow release to the desired site of action.
- Gelling agents such as hyaluronic acid, may also be useful as depot agents.
- the glucagon analogues of the invention may also be formulated as a slow release implantation device for extended and sustained administration of the glucagon peptide analogue.
- sustained release formulations may be in the form of a patch positioned externally on the body.
- sustained release formulations include composites of biocompatible polymers, such as poly(lactic acid), poly(lactic-co-glycolic acid), methylcellulose, hyaluronic acid, sialic acid, silicate, collagen, liposomes and the like.
- Sustained release formulations may be of particular interest when it is desirable to provide a high local concentration of a glucagon analogue of the invention.
- the glucagon analogue may be utilized in the form of a sterile-filled vial or ampoule containing a pharmaceutically sufficient amount of the peptide, in either unit dose or multi-dose amounts.
- the vial or ampoule may contain the glucagon analogue and the desired carrier, as an administration ready formulation.
- the vial or ampoule may contain the glucagon peptide in a form, such as a lyophilized form, suitable for reconstitution in a suitable carrier, such as sterile water or phosphate-buffered saline.
- the glucagon analogue may be formulated for administration by other routes.
- Oral dosage forms such as tablets, capsules and the like, can be formulated in accordance with standard pharmaceutical practice.
- Nasal dosage forms can be formulated with addition of enhancers, such as Chitosan or detergents such as Tween 20, Tween 80, Poloxamers e.g. Pluronic F-68, Pluronic F-127; Brij 35, Brij 72, cremophor EL.
- enhancers such as Chitosan or detergents such as Tween 20, Tween 80, Poloxamers e.g. Pluronic F-68, Pluronic F-127; Brij 35, Brij 72, cremophor EL.
- the therapeutic dosing and regimen most appropriate for patient treatment will of course vary with the disease or condition to be treated, and according to the patient's weight and other parameters. Without wishing to be bound by any particular theory, it is expected that doses, in the ⁇ g/kg range, and shorter or longer duration or frequency of treatment may produce therapeutically useful results.
- the therapeutic regimen may include the administration of maintenance doses appropriate for preventing tissue regression that occurs following cessation of initial treatment.
- the dosage sizes and dosing regimen most appropriate for human use may be guided by the results obtained by the present invention, and may be confirmed in property designed clinical trials.
- An effective dosage and treatment protocol may be determined by conventional means, starting with a low dose in laboratory animals and then increasing the dosage while monitoring the effects, and systematically varying the dosage regimen as well. Numerous factors may be taken into consideration by a clinician when determining an optimal dosage for a given subject. Such considerations are known to the skilled person.
- a human dose of a glucagon peptide according to the invention may in one embodiment be from about 0.1 ⁇ g/kg body weight/day to about 10 mg/kg/day or 10 ⁇ g/kg body weight/day to about 10 mg/kg/day.
- the peptides of the present invention are useful as a pharmaceutical agent for preventing increasing body weight or promoting loss of body weight. They are therefore useful for treating an individual suffering from excess body weight or obesity, including morbid obesity, metabolic syndrome, type-2 diabetes, hypertension, atherosclerois, arteriosclerosis and coronary heart diseases.
- Membranes prepared from cells, which express either the hGlucagon-R or hGLP-1-R will be incubated with 30 - 100 pM [ 125 I]GLP-1, [ 125 I]glucagon in the absence or presence of increasing concentrations (10 -12 -10 -6 M) of test peptides in 100 ⁇ l binding buffer (25 mM HEPES, 2.5 mM CaCl 2 , 1 mM MgCl 2 , & 0.1% BSA, pH 7.4).
- Non-specific binding will be defined at 1 ⁇ M Glucagon or GLP-1.
- the assay mixtures will be incubated for 30 min at 37°C followed by rapid filtration on Unifilters (GF/C) that have been presoaked in 0.5% polyethylenimin for at least 120 min before use.
- the filters will be washed 3 times with buffer, dried for 90 min at 60° C, and counted in a TopCount scintillation counter in the presence of scintillation cocktail.
- IC50 - values will be estimated by computer aided curve fitting.
- the cDNA encoding either the human glucagon receptor (Glucagon-R) (primary accession number P47871) or the human glucagon-like peptide 1 receptor (GLP-1R) (primary accession number P43220) were cloned from the cDNA clones BC104854 (MGC:132514/IMAGE:8143857) or BC112126 (MGC:138331/IMAGE:8327594), respectively.
- the DNA encoding the Glucagon-R or the GLP-1-R was amplified by PCR using primers encoding terminal restriction sites for subcloning.
- the 5'-end primers additionally encoded a near Kozak consensus sequence to ensure efficient translation.
- the PCR products encoding the Glucagon-R or the GLP-1-R were subcloned into a mammalian expression vector.
- the fidelity of the DNA encoding the Glucagon-R and the GLP-1-R was confirmed by DNA sequencing.
- the mammalian expression vector additionally encodes for G418 resistance, transfected cells may be selected by applying selection pressure with G418. Cells exhibiting G418 resistance will most likely also express the Glucagon-R or the GLP-1-R.
- the mammalian expression vectors encoding the Glucagon-R or the GLP-1-R were transfected into HEK293 cells by a standard calcium phosphate transfection method.
- HEK293 cells expressing the hGlucagon-R, or hGLP-1-R are seeded at 40,000 cells per well in 96well microtiter plates coated with 0.01 % poly-L-lysine and grown for 1 day in culture in 100 ⁇ M growth medium. On the day of analysis, growth medium is removed and the cells washed once with 200 ⁇ l Tyrode buffer. Cells are incubated in 100 ⁇ l Tyrode buffer containing increasing concentrations of test peptides, 100 ⁇ M IBMX, and 6 mM glucose for up 15 min at 37° C. The reaction is stopped by addition of 25 ⁇ l 0.5 M HCl and incubated on ice for 60 min. The cAMP content is estimated using the FlashPlate® cAMP kit from Perkin-Elmer. EC 50 and relative efficacy are estimated by computer aided curve fitting.
- Efficacious glucagon/GLP-1 receptor agonists are tested on 9 - 15 weeks old, 40 C57BI/6J male mice which have been kept on a High Fat Diet (HFD) - 60% high-fat food (Cat. No. D12492: 20% protein, 20% carbohydrate, and 60% fat, 5.2 kcal/g; Research Diets, New Jersey, USA, for 4 weeks.
- the high-fat food contains soybean oil (25/773.85 g) and lard (245/773.85 g).
- DIO-mice are treated with vehicle or co-agonists for 2 - 4 weeks by bolus administration (s.c.) twice daily. Body weight is monitored daily throughout the experiment. At the end of the experimental period animals are sacrificed, blood collected for analysis of glycated hemoglobin and a range of hormones and peptides involved in regulation of appetite, food intake, body weight, and energy balances. In addition, the epididymal/perigonadal fat pads and retroperitoneal fat (WAT) as well as the intrascapular Brown Adipose Tissue (BAT) are dissected out and weighed.
- WAT retroperitoneal fat
- BAT intrascapular Brown Adipose Tissue
- the peptides used in the experiment have the following analytical data: Drug Name MW (g/mol) Peptide Content Purity Solvent Exendin-4 4187 88 98 PBS (Compound 1) Oxyntomodulin 4450 83 91 PBS (Compound 2) Compound 3 3365,7 83.1 90 PBS
- mice Prior to initiation of drug treatment the animals were randomized into groups of 10 animals each with similar average body weight (BW) and an eye blood sample (1 ml (EDTA)) were obtained from all animals (Week 10 of age). On week 7, 8, 9 and 10 (week 11, 12, 13 and 14 of age) the mice were treated twice daily s.c. with Exendin-4, oxyntomodulin, Compound 3 or vehicle. One group of animals was maintained on regular chow so as to serve as a non-obese/non-diabetic control group. To make the stress of handling the animals comparable to the other groups these animals were treated with PBS in the same regimen as the tested peptides. Throughout the study, body weights were obtained daily, which were used to calculate dose of the drugs.
- BW body weight
- EDTA eye blood sample
- Figure 1 is a column diagram showing body weight gain in high fat fed (DIO) mice treated s.c. with vehicle, Exendin-4 amide (1-39) (Compound 1, H-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH 2 ), oxyntomodulin (Compound 2, H-HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA-OH) and the peptide Compound 3 for 28 days (animals eating chow are included for comparison).
- the figure shows that s.c. bolus administration of 500 nmol/kg twice daily of Compound 3 is able to reduce body weight gain comparable to oxyntomodulin treatment.
- Figure 2 is a chart showing that the weight reducing effect of Compound 3 (same control peptides as in Fig. 1 ) is sustained over time comparable to oxyntomodulin treatment and significantly different from exendin-4 treatment.
Claims (12)
- Composé de la formule:
R1-Z1-HSQGTFTSDYSKYLDRARADDFVAWLKST-Z2-R2
où:R1 est hydrogène, alkyleC1-4 (par exemple méthyle), acétyle, formyle, benzoyle ou trifluoroacétyle;R2 est NH2 ou OH;Z1 et Z2 sont indépendamment absents ou une séquence de peptides de 1-20 unités d'acides aminés sélectionnées dans le groupe consistant en Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His, Met, Har, Dbu, Dpr et Om;ou un sel pharmaceutiquement acceptable, complexe de coordination d'ions métalliques, ester ou hydrate de celui-ci. - Composé selon la revendication 1, de la formule:
R1-HSQGTFTSDYSKYLDRARADDFVAWLKST-R2
où:R1 est hydrogène, alkyleC1-4 (par exemple méthyle), acétyle, formyle, benzoyle ou trifluoroacétyle;R2 est NH2 ou OH;ou un sel pharmaceutiquement acceptable, complexe de coordination d'ions métalliques, ester ou hydrate de celui-ci. - Composé selon la revendication 1, de la formule:
H-HSQGTFTSDYSKYLDRARADDFVAWLKST-NH2
ou un sel pharmaceutiquement acceptable, complexe de coordination d'ions métalliques, ester ou hydrate de celui-ci. - Acide nucléique codant pour un composé ayant la séquence
Z1-HSQGTFTSDYSKYLDRARADDFVAWLKST-Z2
où Z1 et Z2 sont indépendamment absents ou une séquence de peptides de 1-20 unités d'acide aminé sélectionnées dans le groupe consistant en Ala, Leu, Ser, Thr, Tyr, Asn, Gln, Asp, Glu, Lys, Arg, His et Met. - Vecteur d'expression comprenant un acide nucléique selon la revendication 4.
- Cellule hôte comprenant un acide nucléique selon la revendication 4 ou un vecteur d'expression selon la revendication 5.
- Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications 1 à 3, en mélange avec un support pharmaceutiquement acceptable.
- Utilisation d'un composé selon l'une quelconque des revendications 1 à 3 pour la préparation d'un médicament pour empêcher un gain de poids ou pour encourager une perte de poids.
- Utilisation selon la revendication 8, dans laquelle le médicament est pour l'administration à un sujet souffrant d'obésité, d'obésité morbide, le syndrome métabolique, de diabète de type 2, hypertension, d'athérosclérose, d'artériosclérose, de maladie coronarienne ou de stéatose de foie non-alcoolique.
- Composé selon l'une quelconque des revendications 1 à 3 pour utilisation dans une méthode de traitement médical.
- Composé selon l'une quelconque des revendications 1 à 3, pour utilisation dans une méthode pour empêcher un gain de poids ou pour encourager une perte de poids chez un sujet.
- Composé selon la revendication 11, où le sujet souffre d'obésité, d'obésité morbide, de syndrome métabolique, de diabète de type 2, d'hypertension, d'athérosclérose, d'artériosclérose, de maladie coronarienne ou de stéatose de foie non-alcoolique.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08762369A EP2158214B1 (fr) | 2007-06-15 | 2008-06-16 | Analogues du glucagon |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0711673A GB0711673D0 (en) | 2007-06-15 | 2007-06-15 | Glucagon analogues |
EP07016032A EP2025684A1 (fr) | 2007-08-15 | 2007-08-15 | Analogues du glucagon |
US18807P | 2007-10-24 | 2007-10-24 | |
EP08762369A EP2158214B1 (fr) | 2007-06-15 | 2008-06-16 | Analogues du glucagon |
PCT/GB2008/002041 WO2008152403A1 (fr) | 2007-06-15 | 2008-06-16 | Analogues du glucagon |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2158214A1 EP2158214A1 (fr) | 2010-03-03 |
EP2158214B1 true EP2158214B1 (fr) | 2011-08-17 |
Family
ID=39709376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08762369A Not-in-force EP2158214B1 (fr) | 2007-06-15 | 2008-06-16 | Analogues du glucagon |
Country Status (6)
Country | Link |
---|---|
US (1) | US7994122B2 (fr) |
EP (1) | EP2158214B1 (fr) |
JP (1) | JP5385266B2 (fr) |
AT (1) | ATE520714T1 (fr) |
DK (1) | DK2158214T3 (fr) |
WO (1) | WO2008152403A1 (fr) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056362A2 (fr) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees |
KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-항진물질 |
ES2558155T3 (es) * | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
PA8830501A1 (es) | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
SG192405A1 (en) * | 2008-06-17 | 2013-08-30 | Univ Indiana Res & Tech Corp | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
PL2370460T3 (pl) * | 2008-12-15 | 2014-09-30 | Zealand Pharma As | Analogi glukagonu |
CN102292348B (zh) | 2008-12-15 | 2015-07-08 | 西兰制药公司 | 胰高血糖素类似物 |
KR20110126589A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
CA2747155A1 (fr) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Analogues du glucagon |
JP2012512903A (ja) | 2008-12-19 | 2012-06-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
SG176858A1 (en) | 2009-06-16 | 2012-02-28 | Univ Indiana Res & Tech Corp | Gip receptor-active glucagon compounds |
AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
CN102892425A (zh) * | 2010-01-20 | 2013-01-23 | 西兰制药公司 | 心脏病症的治疗 |
EP2528618A4 (fr) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité |
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
JP2013523620A (ja) | 2010-03-26 | 2013-06-17 | ノヴォ ノルディスク アー/エス | 新規のグルカゴンアナログ |
RU2559320C2 (ru) | 2010-03-26 | 2015-08-10 | Ново Нордиск А/С | Новые аналоги глюкагона |
DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
CN103003300B (zh) | 2010-04-27 | 2017-06-09 | 西兰制药公司 | Glp‑1受体激动剂和胃泌素的肽缀合物及其用途 |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
UY33462A (es) * | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
AP2013006671A0 (en) * | 2010-06-24 | 2013-01-31 | Zealand Pharma As | Glucagon analogues |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
MA34885B1 (fr) | 2010-12-22 | 2014-02-01 | Indiana Unversity Res And Technology Corp | Analogues du glucagon presentant una ctivite de recepteur de gip |
AU2012208349A1 (en) | 2011-01-20 | 2013-07-18 | Zealand Pharma A/S | Combination of acylated glucagon analogues with insulin analogues |
WO2012121746A2 (fr) * | 2011-03-09 | 2012-09-13 | The General Hospital Corporation | Imagerie de la masse des cellules bêta |
CA2830974A1 (fr) | 2011-03-28 | 2012-10-04 | Jesper F. Lau | Nouveaux analogues de glucagon |
WO2012150503A2 (fr) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1 |
EP2707713A2 (fr) | 2011-05-10 | 2014-03-19 | Zealand Pharma A/S | Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1 |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
EP2567959B1 (fr) | 2011-09-12 | 2014-04-16 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
KR20140070612A (ko) | 2011-09-23 | 2014-06-10 | 노보 노르디스크 에이/에스 | 신규 글루카곤 유사체 |
WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
MX2014005351A (es) | 2011-11-03 | 2014-05-28 | Zealand Pharma As | Conjugados de gastrina peptidicos de agonistas de receptor glp-1. |
AP2014007797A0 (en) | 2011-12-23 | 2014-07-31 | Boehringer Ingelheim Int | Glucagon analogues |
WO2013098408A1 (fr) | 2011-12-30 | 2013-07-04 | Zealand Pharma A/S | Conjugués peptidiques agonistes des récepteurs de la cck et du glucagon |
AR090937A1 (es) | 2012-05-03 | 2014-12-17 | Zealand Pharma As | Compuestos agonista duales de gip-glp-1 y metodos para usarlos |
SG11201407860PA (en) | 2012-06-14 | 2014-12-30 | Sanofi Sa | Exendin-4 peptide analogues |
CN109456400A (zh) | 2012-07-23 | 2019-03-12 | 西兰制药公司 | 胰高血糖素类似物 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
WO2014049610A2 (fr) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides en tant que triples agonistes des récepteurs de gip, glp-1 et glucagon |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
EP2911655A1 (fr) | 2012-10-24 | 2015-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibiteurs de la kinase tpl2 pour prévenir ou traiter le diabète et favoriser la survie de cellules |
WO2014096150A1 (fr) | 2012-12-21 | 2014-06-26 | Sanofi | Agonistes du glp1/gip double ou du glp1/gip/glucagon trigonal |
WO2014158900A1 (fr) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Conjugués d'insuline-incrétine |
US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
DK2976325T3 (en) | 2013-03-21 | 2017-06-06 | Sanofi Aventis Deutschland | SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID |
AR095986A1 (es) | 2013-04-03 | 2015-11-25 | Sanofi Sa | Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas |
WO2014170496A1 (fr) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Co-agonistes stables du récepteur du glucagon/glp -1 à action retardée et à usage médical |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
PT3057984T (pt) | 2013-10-17 | 2018-10-24 | Boehringer Ingelheim Int | Análogos de glucagon acilados |
CN105849122B (zh) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
CA2929107C (fr) | 2013-11-06 | 2023-09-26 | Zealand Pharma A/S | Composes agonistes triples glucagon-glp-1-gip |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
WO2015086730A1 (fr) | 2013-12-13 | 2015-06-18 | Sanofi | Analogues peptidiques de l'exendine 4 non acylés |
EP3080154B1 (fr) | 2013-12-13 | 2018-02-07 | Sanofi | Agonistes doubles du récepteur glp-1/gip |
TW201609800A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 做為雙重glp-1/升糖素受體促效劑之艾塞那肽-4胜肽類似物 |
WO2015086733A1 (fr) | 2013-12-13 | 2015-06-18 | Sanofi | Agonistes mixtes des récepteurs du glp-1/glucagon |
WO2015124612A1 (fr) | 2014-02-18 | 2015-08-27 | Novo Nordisk A/S | Analogues du glucagon stables et leur utilisation dans le traitement de l'hypoglycémie |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
CN108271356A (zh) | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
EP3985016A1 (fr) | 2014-10-29 | 2022-04-20 | Zealand Pharma A/S | Composés agonistes de gip et procédés associés |
TN2017000271A1 (en) | 2014-12-30 | 2018-10-19 | Hanmi Pharm Ind Co Ltd | Glucagon derivative having improved stability |
MY175669A (en) | 2015-02-17 | 2020-07-03 | Lilly Co Eli | Nasal powder formulation for treatment of hypoglycemia |
AR103954A1 (es) | 2015-03-18 | 2017-06-14 | Zealand Pharma As | Análogos de amilina |
ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
WO2016168388A2 (fr) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Thérapies pour l'obésité, le diabète et indications associées |
US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
WO2016198628A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine-4 non-acylée comme agonistes doubles du récepteur glp -1/glucagon |
WO2016198624A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip |
NZ739250A (en) | 2015-06-30 | 2024-02-23 | Hanmi Pharmaceutical Co Ltd | Glucagon derivative and a composition comprising a long acting conjugate of the same |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
BR112018013530A2 (pt) | 2015-12-31 | 2018-12-04 | Hanmi Pharm. Co., Ltd. | ?peptídeo isolado, polinucleotídeo e composição farmacêutica? |
WO2017214543A1 (fr) * | 2016-06-09 | 2017-12-14 | Amidebio, Llc | Analogues du glucagon et procédés d'utilisation de ces derniers |
JP7208020B2 (ja) | 2016-06-29 | 2023-01-18 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途 |
PL3494120T3 (pl) | 2016-08-05 | 2021-09-20 | Boehringer Ingelheim International Gmbh | Pochodne oksadiazolopirydyny do zastosowania jako inhibitory o-acylotransferazy greliny (goat) |
AR109514A1 (es) | 2016-09-09 | 2018-12-19 | Zealand Pharma As | Análogos de amilina |
AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
BR112019010624A2 (pt) | 2016-12-09 | 2019-10-22 | Zealand Pharma As | agonistas duplos de glp-1/glp-2 acilados e composição |
MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
PE20210174A1 (es) | 2018-02-02 | 2021-01-29 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) |
EP3746449B1 (fr) | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Dérivés d'oxadiazolopyridine à substitution pyrazole et indazole destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyl transférase (goat) |
MX2020008116A (es) | 2018-02-02 | 2020-09-25 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
AU2019410643A1 (en) | 2018-12-21 | 2021-08-12 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific protein |
TWI771669B (zh) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
AU2020384729A1 (en) | 2019-11-11 | 2022-04-14 | Boehringer Ingelheim International Gmbh | NPY2 receptor agonists |
WO2021233882A1 (fr) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Procédé de fabrication de 7-amino-5-méthyl- [1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle |
WO2022029231A1 (fr) | 2020-08-07 | 2022-02-10 | Boehringer Ingelheim International Gmbh | Agonistes du récepteur npy2 solubles |
CA3215858A1 (fr) | 2021-04-27 | 2022-11-03 | Zhenhuan ZHENG | Combinaison d'un agoniste des recepteurs de l'amertume et d'un compose de signalisation intestinale |
GB202109087D0 (en) | 2021-06-24 | 2021-08-11 | Norwegian Univ Sci & Tech Ntnu | Therapeutic methods and devices |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
ATE290014T1 (de) | 1996-09-09 | 2005-03-15 | Zealand Pharma As | Festphasen-peptidsynthese |
NZ504258A (en) | 1997-11-14 | 2002-12-20 | Amylin Pharmaceuticals Inc | Exendin 3 and 4 agonist compounds for the treatment of diabetes |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
EP1076066A1 (fr) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides abaissant le taux de glucose sanguin |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
WO2006134340A2 (fr) * | 2005-06-13 | 2006-12-21 | Imperial Innovations Limited | Nouveaux composes et leurs effets sur le comportement alimentaire |
US20090202497A1 (en) | 2005-08-23 | 2009-08-13 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-항진물질 |
EP2025684A1 (fr) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Analogues du glucagon |
-
2008
- 2008-06-16 AT AT08762369T patent/ATE520714T1/de active
- 2008-06-16 EP EP08762369A patent/EP2158214B1/fr not_active Not-in-force
- 2008-06-16 JP JP2010511724A patent/JP5385266B2/ja not_active Expired - Fee Related
- 2008-06-16 DK DK08762369.0T patent/DK2158214T3/da active
- 2008-06-16 US US12/664,534 patent/US7994122B2/en not_active Expired - Fee Related
- 2008-06-16 WO PCT/GB2008/002041 patent/WO2008152403A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
ATE520714T1 (de) | 2011-09-15 |
WO2008152403A1 (fr) | 2008-12-18 |
DK2158214T3 (da) | 2011-12-05 |
US20100204105A1 (en) | 2010-08-12 |
US7994122B2 (en) | 2011-08-09 |
EP2158214A1 (fr) | 2010-03-03 |
JP5385266B2 (ja) | 2014-01-08 |
JP2010529849A (ja) | 2010-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2158214B1 (fr) | Analogues du glucagon | |
JP7211712B2 (ja) | グルカゴン受容体アゴニスト | |
EP2025684A1 (fr) | Analogues du glucagon | |
US8685919B2 (en) | Glucagon analogues | |
US20160304576A1 (en) | Glucagon analogues | |
RU2559320C2 (ru) | Новые аналоги глюкагона | |
US8642541B2 (en) | Glucagon analogues | |
US8642540B2 (en) | Glucagon analogues | |
US8680049B2 (en) | Glucagon analogues | |
EP2694095B1 (fr) | Compositions comprenant des analogues du glucagon et leurs procédés de fabrication et d'utilisation | |
JP6054742B2 (ja) | アシル化グルカゴン類似体 | |
EP2051995B1 (fr) | Analogues sélectifs du peptide 2 de type glucagon (glp-2) | |
US20230265151A1 (en) | Gip/glp1 co-agonist compounds | |
ES2371375T3 (es) | Análogos del glucagón. | |
OA16287A (en) | Glucagon analogues. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20091231 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
17Q | First examination report despatched |
Effective date: 20100504 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ZEALAND PHARMA A/S |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008008966 Country of ref document: DE Effective date: 20111103 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2371375 Country of ref document: ES Kind code of ref document: T3 Effective date: 20111230 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20110817 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111217 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111219 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111117 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111118 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E012757 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20120521 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120328 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008008966 Country of ref document: DE Effective date: 20120521 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20120726 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120630 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120616 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20111117 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20130514 Year of fee payment: 6 Ref country code: TR Payment date: 20130527 Year of fee payment: 6 Ref country code: HU Payment date: 20130523 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110817 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120616 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20140425 Year of fee payment: 7 Ref country code: AT Payment date: 20140428 Year of fee payment: 7 Ref country code: NL Payment date: 20140425 Year of fee payment: 7 Ref country code: CH Payment date: 20140425 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20140425 Year of fee payment: 7 Ref country code: BE Payment date: 20140428 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140617 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140616 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20150724 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140617 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20150630 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 520714 Country of ref document: AT Kind code of ref document: T Effective date: 20150616 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150617 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20150701 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150701 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150616 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20160420 Year of fee payment: 9 Ref country code: DE Payment date: 20160427 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20160419 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140616 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602008008966 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20170616 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20180228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170616 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170630 |